# STORM Therapeutics

> STORM Therapeutics is a Cambridge, UK biotechnology company pioneering the field of RNA epigenetics. It designs small-molecule inhibitors of RNA-modifying enzymes to treat cancer and other diseases. Its lead drug, STC-15, is the first RNA-modifying enzyme inhibitor to reach human clinical trials, now in a Phase 2 study for sarcoma.

- **Founded:** 2015
- **Headquarters:** Cambridge, United Kingdom
- **Founders:** Tony Kouzarides (Scientific Founder (Professor, University of Cambridge)), Eric Miska (Scientific Co-Founder (Professor, University of Cambridge))
- **Team size:** Approximately 14 (reported); company has described a lean R&D-focused organization
- **Products:** STC-15, METTL1 inhibitor program, RNA drug discovery & analytics platform
- **Notable:** Developed STC-15, the first RNA-modifying enzyme inhibitor to enter human clinical trials, Published in Nature showing its first-in-class METTL3 inhibitor is effective against AML, Published in Cancer Discovery showing METTL3 inhibition induces anti-tumour immunity

## Products & services

- **STC-15** — A first-in-class, oral small-molecule inhibitor of METTL3 - the enzyme that methylates messenger RNA (m6A). The first RNA-modifying enzyme inhibitor to enter human clinical trials; now in a Phase 2 monotherapy study in selected sarcomas after showing durable tumor regression in Phase 1.
- **METTL1 inhibitor program** — First-in-class inhibitors of the tRNA methyltransferase METTL1, presented at the ESMO Targeted Anticancer Therapies Congress.
- **RNA drug discovery & analytics platform** — A proprietary platform combining RNA mass spectrometry and target biology to identify and validate RNA-modifying enzyme targets and design first-in-class small molecules against them.

## Achievements

- Developed STC-15, the first RNA-modifying enzyme inhibitor to enter human clinical trials
- Published in Nature showing its first-in-class METTL3 inhibitor is effective against AML
- Published in Cancer Discovery showing METTL3 inhibition induces anti-tumour immunity
- Demonstrated durable tumor regression across multiple sarcoma subtypes in Phase 1
- Raised $56M Series C (April 2026) backed entirely by existing investors
- Founder Tony Kouzarides awarded a British knighthood for services to healthcare innovation

## Latest updates

- **2026-04** — Secured $56M Series C financing and dosed first patient in Phase 2 sarcoma trial of STC-15.
- **2026-01** — Announced strategic collaboration with AlidaBio to measure m6A RNA modifications in STC-15 patient samples.

## Links

- Website: https://stormtherapeutics.com
- LinkedIn: https://www.linkedin.com/company/storm-therapeutics-limited
- Twitter/X: https://twitter.com/storm_tx

---

Profile page: https://yespress.io/storm-therapeutics-limited
Published by YesPress — https://yespress.io
Last updated: 2026-06-08